JAMES WILLIAM YOUNG

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc Langerhans-type and monocyte-derived human dendritic cells have different susceptibilities to mRNA electroporation with distinct effects on maturation and activation: implications for immunogenicity in dendritic cell-based immunotherapy
    David J Chung
    Laboratory of Cellular Immunobiology, New York, NY, USA
    J Transl Med 11:166. 2013
  2. ncbi request reprint Dendritic cells in transplantation and immune-based therapies
    James W Young
    Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
    Biol Blood Marrow Transplant 13:23-32. 2007
  3. ncbi request reprint Dendritic cells: expansion and differentiation with hematopoietic growth factors
    J W Young
    Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY 10021 6094, USA
    Curr Opin Hematol 6:135-44. 1999
  4. ncbi request reprint Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation
    Gudrun Ratzinger
    Laboratory of Cellular Immunobiology, Department of Medicine, Weill Medical College of Cornell University, New York, NY, USA
    Blood 101:1422-9. 2003
  5. doi request reprint Sirolimus (rapamycin) induced proteinuria in a patient undergoing allogeneic hematopoietic stem cell transplant
    Kenar D Jhaveri
    Transplantation 86:180-1. 2008
  6. doi request reprint Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings
    Hugo Castro-Malaspina
    The Allogeneic Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Biol Blood Marrow Transplant 14:458-68. 2008
  7. ncbi request reprint Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure
    Joseph H Chewning
    Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Biol Blood Marrow Transplant 13:1313-23. 2007
  8. pmc T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin
    Ann A Jakubowski
    Adult Allogeneic Bone Marrow Transplant Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY 10065, USA
    Blood 110:4552-9. 2007
  9. ncbi request reprint Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant
    David M Weinstock
    Adult Allogeneic Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Biol Blood Marrow Transplant 13:615-21. 2007
  10. ncbi request reprint Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies
    Trudy N Small
    Department of Pediatrics, Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Biol Blood Marrow Transplant 13:235-44. 2007

Collaborators

Detail Information

Publications25

  1. pmc Langerhans-type and monocyte-derived human dendritic cells have different susceptibilities to mRNA electroporation with distinct effects on maturation and activation: implications for immunogenicity in dendritic cell-based immunotherapy
    David J Chung
    Laboratory of Cellular Immunobiology, New York, NY, USA
    J Transl Med 11:166. 2013
    ..A detailed comparative evaluation of the effects of mRNA electroporation on LCs versus moDCs, however, is needed...
  2. ncbi request reprint Dendritic cells in transplantation and immune-based therapies
    James W Young
    Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
    Biol Blood Marrow Transplant 13:23-32. 2007
    ..The use of defined DC subtypes to stimulate both innate and adaptive immunity, either in combination or in a prime-boost vaccine sequence, may prove most useful clinically by harnessing both effector cell compartments...
  3. ncbi request reprint Dendritic cells: expansion and differentiation with hematopoietic growth factors
    J W Young
    Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY 10021 6094, USA
    Curr Opin Hematol 6:135-44. 1999
    ..This has rendered dendritic cells accessible to detailed experimental evaluations and clinical applications. Dendritic cells provide a powerful means of controlling both normal and pathologic immunity...
  4. ncbi request reprint Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation
    Gudrun Ratzinger
    Laboratory of Cellular Immunobiology, Department of Medicine, Weill Medical College of Cornell University, New York, NY, USA
    Blood 101:1422-9. 2003
    ..Whether these results support a separation of deleterious from beneficial graft-host interactions at the level of antigen presentation, rather than solely at the level of T cells, will require further evaluation...
  5. doi request reprint Sirolimus (rapamycin) induced proteinuria in a patient undergoing allogeneic hematopoietic stem cell transplant
    Kenar D Jhaveri
    Transplantation 86:180-1. 2008
  6. doi request reprint Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings
    Hugo Castro-Malaspina
    The Allogeneic Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Biol Blood Marrow Transplant 14:458-68. 2008
    ....
  7. ncbi request reprint Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure
    Joseph H Chewning
    Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Biol Blood Marrow Transplant 13:1313-23. 2007
    ....
  8. pmc T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin
    Ann A Jakubowski
    Adult Allogeneic Bone Marrow Transplant Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY 10065, USA
    Blood 110:4552-9. 2007
    ..Life-threatening OIs occurred in 3 of 52 patients and was fatal in 1. This study demonstrates durable engraftment with a low incidence of GvHD despite the lack of ATG, as well as the curative potential of this regimen...
  9. ncbi request reprint Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant
    David M Weinstock
    Adult Allogeneic Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Biol Blood Marrow Transplant 13:615-21. 2007
    ..The high mortality of VRE in the early posttransplant period supports the use of empiric antibiotics with activity against VRE during periods of fever and neutropenia in colonized patients...
  10. ncbi request reprint Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies
    Trudy N Small
    Department of Pediatrics, Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Biol Blood Marrow Transplant 13:235-44. 2007
    ..For 18 patients with MDS (< or = RAEB-2) or high-risk myeloproliferative disorder, the estimated 3 year DFS is 61%. These data demonstrate the curative potential of this regimen in patients with high-risk myeloid malignancies...
  11. ncbi request reprint Direct evidence for new T-cell generation by patients after either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplantations
    Sharon R Lewin
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY
    Blood 100:2235-42. 2002
    ..T-cell neogenesis, appropriate to age but delayed in adult recipients of T-cell-depleted allografts, justifies interventions to hasten this process and to stimulate desirable cellular immune responses...
  12. pmc Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants
    Dana Jaffe
    Department of Pediatrics, Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Blood 108:2470-5. 2006
    ....
  13. ncbi request reprint Expression of a functional eotaxin (CC chemokine ligand 11) receptor CCR3 by human dendritic cells
    Sylvie Beaulieu
    Laboratory of Cellular Physiology and Immunology, The Rockefeller University and Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College, Cornell University, New York, NY 10021, USA
    J Immunol 169:2925-36. 2002
    ..We postulate that expression of CCR3 may underlie situations where both DCs and eosinophils accumulate in vivo, such as the lesions of patients with Langerhans cell granulomatosis...
  14. pmc Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions
    Adam M Boruchov
    Laboratory of Cellular Immunobiology, Hematology Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Clin Invest 115:2914-23. 2005
    ..The data also suggest novel strategies for targeting antigens to the activating or inhibitory FcgammaRs on human DCs to generate either antigen-specific immunity or tolerance...
  15. ncbi request reprint Erythromelalgia precipitated by acral erythema in the setting of thrombocytopenia
    Lisa M Coppa
    Department of Dermatology, New York Presbyterian Hospital, Weill Cornell Center, New York, New York, USA
    J Am Acad Dermatol 48:973-5. 2003
    ....
  16. ncbi request reprint Infection of mature monocyte-derived dendritic cells with human cytomegalovirus inhibits stimulation of T-cell proliferation via the release of soluble CD83
    Brigitte Senechal
    Laboratory of Cellular Immunobiology, Allogenic Transplantation and Clinical Immunology Services, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021 6094, USA
    Blood 103:4207-15. 2004
    ..We have thus discovered a new mechanism by which HCMV infection may establish a nonlytic reservoir in mature moDCs that inhibits DC-mediated T-cell responses...
  17. ncbi request reprint Mature human Langerhans cells derived from CD34+ hematopoietic progenitors stimulate greater cytolytic T lymphocyte activity in the absence of bioactive IL-12p70, by either single peptide presentation or cross-priming, than do dermal-interstitial or monoc
    Gudrun Ratzinger
    Laboratory of Cellular Immunobiology, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 173:2780-91. 2004
    ..These findings merit further comparisons in clinical trials designed to determine the physiologic relevance of these distinctions in activity between LCs and other DCs...
  18. ncbi request reprint Mature myeloid dendritic cell subsets have distinct roles for activation and viability of circulating human natural killer cells
    CHRISTIAN MUNZ
    Laboratory of Viral Immunobiology, The Rockefeller University, New York, NY 10021 6399, USA
    Blood 105:266-73. 2005
    ..Hence, the principal myeloid DCs differ in critical ways regarding the stimulation of NK and T lymphocytes and could be used or targeted accordingly in DC-based immunotherapies...
  19. ncbi request reprint Langerhans cells derived from genetically modified human CD34+ hemopoietic progenitors are more potent than peptide-pulsed Langerhans cells for inducing antigen-specific CD8+ cytolytic T lymphocyte responses
    Jianda Yuan
    Laboratory of Cellular Immunobiology, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 174:758-66. 2005
    ..LCs genetically modified to express fluMP are also more potent stimulators of Ag-specific CD8(+) T cell responses than are peptide-pulsed LCs...
  20. ncbi request reprint Dendritic cells have the option to express IDO-mediated suppression or not
    David H Munn
    Blood 105:2618. 2005
  21. ncbi request reprint Scalable expansion of potent genetically modified human langerhans cells in a closed system for clinical applications
    Jianda Yuan
    Laboratory of Cellular Immunobiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Immunother 30:634-43. 2007
    ..We have thus developed a scalable closed process to expand genetically modified, biologically functional CD34+ hematopoietic progenitor cell-derived LCs for phase I clinical trials...
  22. pmc CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy
    Ping Zhou
    Sloan Kettering Institute, Department of Medicine, New York, NY 10021, USA
    Blood 111:3403-6. 2008
    ..These data provide a rationale for the novel therapeutic targeting of CD32B using the humanized 2B6 MoAb in patients with systemic AL-amyloidosis...
  23. ncbi request reprint Predominant autoantibody production by early human B cell precursors
    Hedda Wardemann
    Laboratory of Molecular Immunology, Rockefeller University, New York, NY 10021, USA
    Science 301:1374-7. 2003
    ..Most of these autoantibodies were removed from the population at two discrete checkpoints during B cell development. Inefficient checkpoint regulation would lead to substantial increases in circulating autoantibodies...
  24. ncbi request reprint Human dendritic cells: potent antigen-presenting cells at the crossroads of innate and adaptive immunity
    Marco Rossi
    Laboratory of Cellular Immunobiology, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Immunol 175:1373-81. 2005
    ..This review will address these developments in an attempt to integrate the activities of different DCs in coordinating innate and adaptive immunity...
  25. ncbi request reprint Langerhans-type dendritic cells genetically modified to express full-length antigen optimally stimulate CTLs in a CD4-dependent manner
    Jianda Yuan
    Laboratory of Cellular Immunobiology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 176:2357-65. 2006
    ..LCs, transduced with a retroviral vector encoding full-length Ag, stimulate potent CTLs directed against multiple epitopes in a CD4(+) Th cell-dependent manner...

Research Grants16

  1. GENETIC MODIFICATION OF HUMAN DENDRITIC CELLS FOR CANCER IMMUNITY
    JAMES WILLIAM YOUNG; Fiscal Year: 2010
    ..These approaches should find their greatest application in treating minimal residual disease after primary therapy.) ..
  2. TUMOR IMMUNITY GENERATED BY DENDRITIC CELLS
    James Young; Fiscal Year: 2009
    ..New and improved approaches for the immune-based treatment of cancer are anticipated, with the most effective application likely being the treatment of minimal residual disease after primary therapy.) ..
  3. GENETIC MODIFICATION OF HUMAN DENDRITIC CELLS FOR CANCER IMMUNITY
    James Young; Fiscal Year: 2007
    ..These approaches should find their greatest application in treating minimal residual disease after primary therapy.) ..
  4. Immune responses to gene-modified, autologous dendritic cell vaccines in melanoma
    James Young; Fiscal Year: 2007
    ..LAY SUMMARY: Genetic alterations of specialized Langerhans-type dendritic cells will be tested for safety, toxicity, and the stimulation of tumor- specific immunity in patients with advanced stage III-IV melanoma.) ..
  5. TUMOR IMMUNITY GENERATED BY DENDRITIC CELLS
    James Young; Fiscal Year: 2007
    ..New and improved approaches for the immune-based treatment of cancer are anticipated, with the most effective application likely being the treatment of minimal residual disease after primary therapy.) ..
  6. Alemtuzumab treatment of steroid-refractory acute GvHD
    James Young; Fiscal Year: 2004
    ..abstract_text> ..
  7. TUMOR IMMUNITY GENERATED BY DENDRITIC CELLS
    JAMES WILLIAM YOUNG; Fiscal Year: 2010
    ..New and improved approaches for the immune-based treatment of cancer are anticipated, with the most effective application likely being the treatment of minimal residual disease after primary therapy.) ..